The common heart medication digoxin enhances survival rates in infants undergoing surgery for single-ventricle heart defects, according to new research.
A recent analysis of the TWILIGHT trial reveals that ticagrelor monotherapy after three months of dual antiplatelet therapy (DAPT) does not increase the risk of revascularization after percutaneous coronary intervention (PCI). In fact, monotherapy with ticagrelor shows a lower bleeding risk compared to continued DAPT. These findings provide insights into the potential benefits of ticagrelor monotherapy as a treatment strategy after PCI.Read More
- Pulse Oximeter Flaws May Limit Black Heart Failure Patients’ Care
- New Suggested Steps Per Day Far Fewer Than Often-Cited 10,000
- Patients With Persistent AFib Are More Likely to Have These Risk Factors
- Too Much Niacin May Increase Heart Disease Risk
- AI Measures Heart Fat in Seconds to Predict Heart Attack Risk